CRIS Current Research Information System

AZZAROLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.025
AS - Asia 11.022
EU - Europa 7.050
AF - Africa 592
SA - Sud America 532
Continente sconosciuto - Info sul continente non disponibili 476
OC - Oceania 14
Totale 30.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.830
VN - Vietnam 3.861
SG - Singapore 2.638
CN - Cina 2.217
IT - Italia 1.580
GB - Regno Unito 1.411
DE - Germania 844
SE - Svezia 762
HK - Hong Kong 638
FR - Francia 442
IN - India 437
BR - Brasile 379
BD - Bangladesh 354
UA - Ucraina 340
RU - Federazione Russa 323
NL - Olanda 303
IE - Irlanda 287
KR - Corea 224
JP - Giappone 186
ZA - Sudafrica 161
CI - Costa d'Avorio 142
FI - Finlandia 142
EE - Estonia 106
CA - Canada 104
CH - Svizzera 104
TG - Togo 92
SC - Seychelles 79
BG - Bulgaria 69
PH - Filippine 64
ES - Italia 61
PL - Polonia 58
TH - Thailandia 58
AT - Austria 54
AR - Argentina 50
ID - Indonesia 50
TR - Turchia 48
NG - Nigeria 47
JO - Giordania 42
BE - Belgio 39
MX - Messico 39
GR - Grecia 36
EC - Ecuador 33
IQ - Iraq 29
PK - Pakistan 27
TW - Taiwan 27
SA - Arabia Saudita 24
IR - Iran 20
EG - Egitto 19
CO - Colombia 14
LT - Lituania 14
AU - Australia 13
JM - Giamaica 13
VE - Venezuela 13
CZ - Repubblica Ceca 12
PE - Perù 12
UZ - Uzbekistan 12
MY - Malesia 11
PY - Paraguay 10
CL - Cile 9
CR - Costa Rica 9
PT - Portogallo 9
LB - Libano 8
TN - Tunisia 8
DK - Danimarca 7
HR - Croazia 7
IL - Israele 7
KE - Kenya 7
DZ - Algeria 6
ET - Etiopia 6
MK - Macedonia 6
AE - Emirati Arabi Uniti 5
AO - Angola 5
BO - Bolivia 5
MA - Marocco 5
NP - Nepal 5
RO - Romania 5
RS - Serbia 5
DO - Repubblica Dominicana 4
GT - Guatemala 4
HU - Ungheria 4
KW - Kuwait 4
SI - Slovenia 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CY - Cipro 3
HN - Honduras 3
MD - Moldavia 3
NI - Nicaragua 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BH - Bahrain 2
CM - Camerun 2
GE - Georgia 2
GH - Ghana 2
GN - Guinea 2
KG - Kirghizistan 2
Totale 30.198
Salva come PNG Salva come JPEG
Città #
Singapore 1.845
Southend 1.226
Fairfield 1.174
Ashburn 1.084
Ho Chi Minh City 944
Hanoi 836
Chandler 719
San Jose 634
Hong Kong 580
Santa Clara 451
Hefei 384
Bologna 329
Wilmington 321
Seattle 314
Houston 311
Princeton 306
Woodbridge 299
Dublin 283
Boardman 277
Dong Ket 258
Beijing 245
Cambridge 230
New York 218
Los Angeles 205
Jacksonville 203
Ann Arbor 186
Council Bluffs 184
Dallas 175
Seoul 174
Lauterbourg 162
Da Nang 158
Tokyo 153
Abidjan 142
Milan 139
Haiphong 124
Westminster 118
Nanjing 117
Buffalo 103
Padova 97
Frankfurt am Main 93
Berlin 92
Lomé 92
Helsinki 86
Bern 81
Rome 78
Munich 77
Medford 76
São Paulo 74
Saint Petersburg 72
Sofia 62
Biên Hòa 58
Dearborn 58
Jinan 58
Shanghai 57
Redondo Beach 52
Hải Dương 50
Johannesburg 49
Shenyang 49
Atlanta 46
San Diego 46
Turin 46
Abeokuta 45
Hebei 45
Changsha 44
Thái Nguyên 43
Amman 42
Florence 42
Ha Long 42
Can Tho 41
Chicago 40
Guangzhou 40
Orem 40
Nanchang 39
Des Moines 37
Amsterdam 36
Bremen 35
Bắc Ninh 35
San Francisco 35
Mülheim 34
Phoenix 34
Bengaluru 33
Hangzhou 33
Quận Bình Thạnh 33
Redmond 33
Brussels 32
Falkenstein 32
London 32
Toronto 32
Turku 32
Barcelona 30
Vienna 30
Vũng Tàu 30
Warsaw 30
Brooklyn 27
Tianjin 27
Bắc Giang 26
Bến Tre 26
Ninh Bình 26
Zhengzhou 25
Lappeenranta 24
Totale 18.502
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 615
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 519
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis 418
Outcomes and survival after TIPS positioning: a single center experience 407
Anorectal emergencies: WSES-AAST guidelines 407
Chronic non allergic rhinitis with neutrophilis (NARNE) and gastroesophageal reflux disease (GERD): A possible correlation? 362
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 340
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure 313
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 304
Monofocal hepatocellular carcinoma: How much does size matter? 298
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 278
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 258
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 256
Intrahepatic Cholestasis of Pregnancy: mRNAs for LIPF and ELOVL4 Genes Are Not Detectable in Circulating Maternal Plasma. 251
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 245
Pattern of macrovascular invasion in hepatocellular carcinoma 244
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 243
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 241
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 239
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 238
Sarcopenia predicts ascitic decompensation and mortality independently of portal hypertension status in patients with advanced chronic liver disease outside the liver transplantation setting 233
Utility of Doppler-Ultrasound and Liver Elastography in the Evaluation of Patients with Suspected Pregnancy-Related Liver Disease 229
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 228
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis 226
The future of dual therapy for hepatitis C virus 224
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 221
Adverse effects of proton pump inhibitors. 220
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 220
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 218
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 218
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 217
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 216
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 214
The changing scenario of hepatocellular carcinoma in Italy: an update 213
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 212
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 206
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 205
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 205
Alisporivir for the treatment of chronic HCV 204
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 201
Diagnostic Approach to Elevated Liver Function Tests during Pregnancy: A Pragmatic Narrative Review 200
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 199
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 198
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 194
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 191
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib. 187
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 185
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 184
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 182
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 182
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 179
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 177
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 177
Terapia cellulare in Epatologia 174
Pharmacological modulation of MRP2 in primary biliary cirrhosis 174
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 174
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 174
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 173
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 173
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 171
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 171
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 166
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 166
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 165
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 165
Porto-sinusoidal vascular disorder in surgical candidates for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes 165
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 164
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 164
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 164
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 163
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 163
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 162
Fatty liver in pregnancy: a narrative review of two distinct conditions 161
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 160
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 160
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 160
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 159
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 158
An unusual cause of weight loss in a young Caucasian man 157
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 157
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 157
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 157
Severe hypernatremia as a predictor of mortality after percutaneous endoscopic gastrostomy (PEG) placement 157
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 156
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 156
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 155
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 155
Chemiluminescence measurement of autotaxin activity in human serum 154
The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis: Sarcopenia predicts ascites and death in cirrhotic patients 153
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 153
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 153
Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests? 153
Graded pneumatic dilation in subtype I and II achalasia: long-term experience in a single center 153
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 150
Reply 150
Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients 149
New practice guidelines on risk stratification and management of portal hypertension: towards a personalized multidisciplinary approach 148
Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient 147
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection 146
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. 146
Totale 20.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.363
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.363
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.261 220 101 160 187 245 144 82 187 137 172 1.173 453
2022/20233.101 343 429 170 380 212 236 114 159 524 98 239 197
2023/20241.030 68 146 54 120 94 225 41 69 63 63 40 47
2024/20254.044 165 616 378 224 610 203 292 127 79 364 211 775
2025/202612.575 1.945 945 931 677 1.090 545 1.559 435 2.229 874 666 679
2026/2027782 782 0 0 0 0 0 0 0 0 0 0 0
Totale 30.711